Financing Quarterly Statistics, Q1 2024

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, January-March 2024

During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.

Qstats Image 1
• Source: Alamy

Biopharma financing during the first quarter of 2024 totaled $30.1bn from 298 deals. The follow-on public offering (FOPO) category made up the greatest proportion (36%) of the aggregate Q1 financing dollars (see Exhibit 1). During Q1, there were 81 FOPOs in all, of which 36 deals totaled $100m or more.

Vaxcyte (vaccines to protect from bacterial diseases) raised the most in the category with its $817m January FOPO. The company will use the proceeds for clinical development of its VAX-24 and VAX-31 pneumococcal conjugate vaccine (PCV) adult and pediatric programs, including the initiation of anticipated Phase III studies for either the VAX-24 or VAX-31 adult programs in 2025 and into 2026; manufacturing scale-up; ongoing research and development of other vaccine candidates; and potential expansion of its research pipeline

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By 

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By 

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Dealmaking Quarterly Statistics, Q1 2025

 
• By 

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.